If the generic doesn't get out there then the pharmaceutical company (with the patent) obviously benefits.
Merck is not dumb. They're not in the business of losing money.
These are the two biggest companies in the cholesterol segment, companies with combined annual revenues of $12 billion, and (the guidelines) could add a couple of billion to each company over five years.
The more the two companies discussed co-heads, the more difficult it became.